{
  "doc_id": "Determina_33-2024_Lumykras",
  "created_date": "2024",
  "country": "IT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "AG FA DET Ricl dell (Det (GU Vi reca cor modi l'Ag disp Serv Vi salu dell sull farm sett nove genn Mini pubb genn Vi dell pubb Gazz GENZIA ITALIANA DEL ARMACO TERMINATED 17 May 2024 classification of the medicinal product for human use Lumykras, within the meaning of Article 8 (10) of the Law of 24 December 1993, No 537. which terminates at No 33/2024). (24A02603) U No 121 of 25-5-2024)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Article 48 of Decree-Law No 269 of 30 September 2003 is amended as follows:",
      "text": "ante Urgent provisions to facilitate the development and repair of public accounts, converted, with amendments, into Law No 326 of 24 November 2003 establishing the Italian Pharmaceutical Agency and, in particular, paragraph 33, which provides for price negotiation for products reimbursed by the National Health Service between the Agency and manufacturers; this is Decree No 245 of 20 September 2004 of the Minister of Health, in consultation with the Ministers of the Public Service and Economy and Finance, containing Regulation laying down the rules for the organisation and functioning of the Italian Food Agency, pursuant to Article 48, paragraph 13, of Decree-Law No 269 of 30 November 2003, converted with modifications, by Act of 24 April 2003 No 326, as last amended by Decree of 8 January 2024, No 3 of the Ministry of Health with regard to the staff of the National Pharmacy Agency, and the function of the General Health Service and the general budget of the Republic of Italy; widowed on the official website of the same institution (Original publication date: 17 April 2024 - Series A/B/A/5), with the date of publication of the Official Gazette No. 1/5 Having regard to the decree of the Minister of Health of 5 April 2024 appointing, with effect from that date, Prof. Robert Giovanni Nistico' as Chairman of the Board of Directors of the Italian Medicines Agency, pursuant to Article 7 of the aforementioned Decree of 20 September 2004, No 245 and its subsequent amendments; Having regard in particular to the Decree by the Minister for Health of 9 February 2024 on the appointment of Dr. Pierluigi Russo as Technical and Scientific Director of the Agenzia Italiana del Farmaco, in accordance with Article 10-bis of the above-mentioned Decree, No 245, dated 28 May 2020, by which the position of Director General No 643 was conferred on Dr. Having regard to the Decision of the Director-General No 643 of 28 May 2020 appointing Dr Francesco Trotta as Head of the HTA and Pharmaceutical Economy Sector, and in particular Article 8 (10) thereof, on the classification of medicinal products which may be administered by the National Health Service, and to Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 amending Directive 2001/83/EC on advanced therapy medicines; Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency; having regard to Legislative Decree No 219 of 24 April 2006 implementing Directive 2001/83/EC (and subsequent amending directives) on a Community code relating to medicinal Products for Human Use; having regards to the Decree of the Minister for Health of 2 August 2019 establishing Criteria and modalities according to which the Italian Agency for Medicines determines, by negotiation, the prices of medicines reimbursed by the Servizio Sanitario Nazionale, published in the Gazzetta Ufficiale della Repubblica Italiana - Serie Generale n. 185 of 24 July 2012; having considered Articles 11 and 12 of Decree-Law No 138-D of 15 September 2012 on the Reimbursement of Medicinal Products, with subsequent amendments to the Emergency Refunds Law of 18 August 2003, converted into a Law on the Promotion of Competition and Protection of the National Health Care Market (Leg. 326 (Prontuario Farmaceutico Nazionale 2006) , published in the Official Journal of the Italian Republic - General Series - No 156 of 7 July 2006; Having regard to the AIFA determination of 27 September 2006 Manoeuvre for the governance of conventional and non-conventional pharmaceutical expenditure requested by the Vistagen B.V. European Pharmaceutical Classification Service, issued in the OJ R.S. - General series - No 227 of 29 September 2006; having regard to AIFA decision No 49/2022 of 1 April 2022, published on 11 May 2022 Classification according to Article 12 (5) of Law No 189 of 8 November 2012 of the medicinal product for human use 'Lykumras', approved by a centralised procedure; Packs: (PVC/ PE/ PVDC/ alu) 240 tablets - A.I.C. No 049858018/ E (based on base 10) - reimbursement class: H - ex-factory price (excluding VAT) € 7,368.00 - retail price (including VAT), € 12,160.24; 120 mg - film-coated tablet - oral use - bottle (HDPE) of 240 (2 × 120) tablets, 0498032/ E (in - base 10) retail price: tablets (multipack) - A.I.C. No 049858020/E (based on 10) - reimbursability class: C. Mandatory discount on the ex-factory price, to be applied to public health facilities, including private health facilities accredited with the National Health Service, as from negotiated conditions. The company, without prejudice to the provisions on the disposal of stocks, in accordance with Article 13 of Decree-Law No 35 of 30 April 2019, converted, with amendments, into Law No 60 of 25 June 2019, undertakes to maintain a constant supply adequate to the needs of the national health service. Contract validity: twenty-four months. For the purpose of prescribing and dispensing the medicinal product, physicians and pharmacists associated with the user centres specifically identified by the regions will be required to complete the computerised data collection sheet available for access through the institutional website of the AIFA, at the following address: The classification Lumykras (sort of medical prescription for sale to the public specialists - onco This publication will be notified at the time of entry into force in Rome, 17 May association for the purposes of supply ione for the purpose of supply d rasib) and the following: medicinal product ica limitativa, to be renewed only on prescription from hospitals (RNRL).",
      "start_page": 1,
      "end_page": 5
    }
  ],
  "_translation_metadata": {
    "processing_timestamp": "2025-08-11T13:42:01.669396",
    "source_file": "Determina_33-2024_Lumykras_cleaned.json",
    "detected_language": "it",
    "was_translation_needed": true,
    "translation_strategy": "nllb_translation",
    "max_input_tokens": 480,
    "target_chunk_tokens": 300,
    "overlap_tokens": 40,
    "table_content_detected": 0,
    "model_available": true,
    "translation_decision": "nllb_processing",
    "model_used": "facebook/nllb-200-3.3B",
    "quality_scores": {
      "overall": 0.8967666658584499,
      "chunk_count": 2,
      "linguistic": {
        "fluency": 0.7217391304347825,
        "accuracy": 0.8361629196491582,
        "consistency": 0.7910798122065728,
        "completeness": 0.8888971684053651,
        "linguistic_composite": 0.8033660111475698
      },
      "domain_specific": {
        "medical_terminology": 1.0,
        "numerical_integrity": 0.8970588235294117,
        "statistical_terms": 1.0,
        "unit_preservation": 1.0,
        "domain_composite": 0.9691176470588235
      },
      "structural": {
        "format_preservation": 0.9,
        "document_integrity": 1.0,
        "information_architecture": 1.0,
        "structural_composite": 0.96
      },
      "empty_translations": 0,
      "missing_content_ratio": 0.0
    },
    "translation_metadata": {
      "model_loaded": true,
      "model_name": "facebook/nllb-200-3.3B",
      "processing_time_seconds": 100.343701,
      "chunks_found": true,
      "total_chunks": 2,
      "chunks_translated": 3,
      "chunks_english": 0,
      "table_chunks_processed": 0,
      "quality_scores": {
        "overall": 0.8967666658584499,
        "chunk_count": 2,
        "linguistic": {
          "fluency": 0.7217391304347825,
          "accuracy": 0.8361629196491582,
          "consistency": 0.7910798122065728,
          "completeness": 0.8888971684053651,
          "linguistic_composite": 0.8033660111475698
        },
        "domain_specific": {
          "medical_terminology": 1.0,
          "numerical_integrity": 0.8970588235294117,
          "statistical_terms": 1.0,
          "unit_preservation": 1.0,
          "domain_composite": 0.9691176470588235
        },
        "structural": {
          "format_preservation": 0.9,
          "document_integrity": 1.0,
          "information_architecture": 1.0,
          "structural_composite": 0.96
        },
        "empty_translations": 0,
        "missing_content_ratio": 0.0
      }
    },
    "total_processing_time_seconds": 103.086051,
    "processing_completed_timestamp": "2025-08-11T13:43:44.755492"
  }
}